Sign In
Buy WVE
$5.76
+0.0700 (+1.23%)
At Close: Jun 03, 2026
Wave Life Sciences Fourth Quarter and Full Year 2024 Financial Results Scheduled for March 4, 2025
08:30am, Tuesday, 25'th Feb 2025
CAMBRIDGE, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transfor
Wave Life Sciences Announces Initiation of Phase 1 INLIGHT Clinical Trial of WVE-007 in Obesity
08:30am, Thursday, 06'th Feb 2025
WVE-007 is a novel, long-acting GalNAc-siRNA targeting INHBE mRNA – a genetically validated target that provides a new approach for healthy, sustainable weight loss (fat loss with muscle preservatio
Wave Life Sciences Is A Buy On Pipeline Prospects
01:35am, Wednesday, 08'th Jan 2025
Wave Life Sciences develops stereopure oligonucleotides targeting genetic mutations, with lead assets in DMD, AATD, and Huntington's Disease showing promising data. Major collaborations with GSK and p
Wave Life Sciences Announces Submission of First Clinical Trial Application for WVE-007 (siRNA Targeting INHBE) in Obesity
08:30am, Monday, 23'rd Dec 2024
WVE-007 is a novel approach for treating obesity and is designed to silence INHBE to achieve healthy, sustainable weight loss through fat burning, muscle maintenance and the potential for once or twic
Wave Life Sciences to Present at 43rd Annual J.P. Morgan Healthcare Conference
08:30am, Monday, 16'th Dec 2024
CAMBRIDGE, Mass., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform
Wave Life Sciences to Present at Jefferies London Healthcare Conference
08:30am, Friday, 15'th Nov 2024
CAMBRIDGE, Mass., Nov. 15, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform
Wave Life Sciences Ltd. (WVE) Q3 2024 Earnings Call Transcript
12:20pm, Tuesday, 12'th Nov 2024
Wave Life Sciences Ltd. (NASDAQ:WVE ) Q3 2024 Results Conference Call November 12, 2024 8:30 AM ET Company Participants Kate Rausch - Vice President, Investor Relations & Corporate Affairs Paul Bolno
Wave Life Sciences (WVE) Reports Q3 Loss, Lags Revenue Estimates
10:01am, Tuesday, 12'th Nov 2024
Wave Life Sciences (WVE) came out with a quarterly loss of $0.47 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to earnings of $0.07 per share a year ago.
Wave Life Sciences (WVE) Expected to Beat Earnings Estimates: Should You Buy?
11:05am, Tuesday, 05'th Nov 2024
Wave Life Sciences (WVE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Wave Life Sciences Highlights Growing Pipeline at Research Day, including INHBE siRNA Program for Obesity and New RNA Editing Programs
04:45pm, Wednesday, 30'th Oct 2024
WVE-007 (INHBE GalNAc-siRNA for obesity) is on track to initiate a clinical trial in 1Q 2025; new preclinical data for WVE-007 demonstrate opportunities for monotherapy, for synergistic use with GLP-1
Wall Street Analysts Predict a 34.53% Upside in Wave Life Sciences (WVE): Here's What You Should Know
10:55am, Monday, 28'th Oct 2024
The average of price targets set by Wall Street analysts indicates a potential upside of 34.5% in Wave Life Sciences (WVE). While the effectiveness of this highly sought-after metric is questionable,
1 Brand-New Big Reason to Buy This Biotech Stock Right Now
05:53am, Thursday, 24'th Oct 2024
This stock currently has a good balance of risk and potential rewards.
What Makes Wave Life Sciences (WVE) a Strong Momentum Stock: Buy Now?
01:01pm, Wednesday, 23'rd Oct 2024
Does Wave Life Sciences (WVE) have what it takes to be a top stock pick for momentum investors? Let's find out.
Korro Bio Is Lagging Wave Life Sciences In RNA Editing. Why It Could Ultimately Lead The Space.
10:50am, Monday, 21'st Oct 2024
Shares of Korro Bio and Wave Life Sciences diverged Monday after an analyst argued Korro is the better way to play the RNA-editing space.
Wave Life Sciences Rockets 70% on Historic RNA Editing Success
07:32am, Friday, 18'th Oct 2024
Wave Life Sciences Ltd. NASDAQ: WVE is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health.
